Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

VOLUNTARY ANNOUNCEMENT
THE SUCCESSFUL COMPLETION OF KEN-VALVE'S FIRST BATCH OF COMMERCIAL IMPLANTATIONS

This announcement is made by Jenscare Scientific Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide the shareholders and potential investors of the Company with updated data in relation to the latest business and new product development of the Group.

The board ("**Board**") of directors ("**Directors**") of the Company is pleased to announce that Ken-Valve, one of the Company's core products of transcatheter aortic valve replacement ("**TAVR**"), has successfully completed its first batch of commercial implantations in a series of hospitals in key provinces and regions of China. The maximum valve size used is 33mm, and the minimum device operation time is approximately 5 minutes. In the recently concluded 2025 West China Minimally Invasive Cardiovascular Congress and the Eighth West China Valve Forum, Ken-Valve successfully completed a number of live-streaming operation cases, aortic valve interventional replacement was successfully performed in multiple patients with complex anatomical structures, among others, including large aortic annulus and severe horizontal heart. Ken-Valve's design features, operational advantages, and scope of application were warmly discussed and concerned by experts attending the meeting.

Ken-Valve, our proprietary first-generation TAVR system, is designed for the treatment of patients with severe aortic regurgitation or combined with aortic stenosis. Ken-Valve is a relatively rare TAVR product for the treatment of aortic regurgitation (or combined with aortic stenosis) in the market. Ken-Valve adopts the integrated positioning anchor design to improve the stability of valve fixation. The delivery system incorporates active steerable design which can effectively improve the coaxiality of valve implantation. With multiple valve sizes up to 33mm, it can meet the urgent and unmet clinical needs of a wide range of patients with the large aortic annulus of aortic regurgitation or combined aortic valve stenosis.

The successful implementations of the first batch of commercial implantation mark the successful launch and smooth progress of Ken-Valve's commercial application in China, and is an important milestone in the commercialization process of the product and the Company. The Company will continue to adopt various measures to take advantage of this market opportunity to expand the coverage of sales networks and to further facilitate the global commercialization of the core products of the Company, including Ken-Valve, LuX-Valve series products, and etc. Meanwhile, the Company will keep optimizing production costs and operating efficiency to achieve its revenue target as soon as practicable.

Cautionary Statement as required by Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately market and/or commercialize Ken-Valve successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Jenscare Scientific Co., Ltd.
Mr. PAN Fei
Executive Director and Chief Executive Officer

Hong Kong, July 21, 2025

As at the date of this announcement, the executive Director is Mr. PAN Fei; the non-executive Directors are Mr. LV Shiwen, Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.